By François Collard, PhD, Bio-Process Knowledge Manager, Pall Biotech
Gene therapies delivered using viral vectors offer exciting potential to welcome a new type of treatment for various disease indications. However, one of the most complex steps to develop and scale for viral vector transient production based on adenovirus (AV), adeno-associated virus (AAV) and lentivirus (LV) is transfection.
Scalability Matters
Drug developers, process equipment vendors and raw material suppliers have been collaborating across the industry to develop practical, cost-effective, platformizable solutions for the rapid development and scale-up of viral vector manufacturing processes. This includes the need for expertise with industrializing the transfection step because most companies will only have transfection experience at the lab scale.
Read more on Labcompare.